[推荐]乙型肝炎基金会2014年年度报告

StephenW

http://www.hepb.org/pdf/2014_Hep_B_Foundation_Annual_Report.pdf
2
Hepatitis B Foundation 2014 Annual Report
The next three years will be the “make-it” period for the Hepatitis B Foundation and its research arm, the
Baruch S. Blumberg Institute. We have imposed an ambitious timeline for results because we believe the opportunity is now, and the need is urgent.
Our world-class research institute—renamed in 2013 as the Baruch S. Blumberg Institute in honor
of our co-founder and Nobel Laureate Dr. Blumberg—is poised to significantly accelerate the pace of research. We have recruited a group of first class scientists to join us fulltime at the Blumberg
Institute in 2015.
Our new scientists, however, aren’t starting from zero. Indeed, they will have a head start since
we have been preparing and building toward this goal for more than two decades. And all of our
scientists have pledged to identify breakthrough therapies for hepatitis B in the next three years.
We want, and plan for, our discoveries to go from the lab into human use as quickly as possible.
We know that this will require drug development experts with pharmaceutical company experience and we have already made arrangements to create technology development partnerships. This means that our scientists can focus on pioneering discoveries and our partners can carry them all the way to the clinic.
Our hope for the next 5 to 10 years is simple—
that a complete cure is found, which will benefit everyone living with chronic hepatitis B worldwide.
We are ready to make a bold new push to truly make hepatitis B history.

New Ways to Treat Hepatitis B

Putting the STING in Hepatitis B:
Using an innovative assay developed in the labs of Drs. Guo and Chang, a new method of treating HBV was discovered. Our small molecule “Stimulator of Interferon Genes” (STING) is one of the most exciting leads in the field and shows
that in tissue culture all detectable viral gene products can be eliminated. This finding was confirmed in a small animal study, too. The STING approach has moved to the front of our research strategies and is one of the more innovative immunotherapeutic approaches.
Guoet al, Antimicrobial Agents & Chemotherapy, 2014.

HBsAg Inhibitors:
We have developed some of the only drugs that target the hepatitis B virus surface
antigen (HBsAg). HBsAg is essential for viral replication and may also help the virus avoid detection by the patient’s immune system. We have produced several
drugs that reduce the amount of HBsAg secreted by infected cells, in tissue culture. Animal results are ongoing, with as yet inconclusive data. But this is a
very promising treatment approach.
Cuconati et al, in preparation.

Capsid Inhibitors:
We have identified novel inhibitors of the virus capsid assembly process. The capsid is the protein shield that surrounds the viral DNA and is an essential protein. It may also play a role in regulating viral gene expression from its
covalently closed circular (ccc) DNA as well as immune evasion. Our new capsid inhibitors have been shown to be potent inhibitors of viral production in vitro (tissue culture) and may even have immune altering functions. One class of our compounds has been validated as active in animal studies, too.
Campagna et al, J Virology, 2013.

Inhibitors of cccDNA:
We have identified compounds that repress hepatitis B cccDNA (Liu et al, 2013, PLOS Pathogens) and there is great interest in their development. Some of these leads were found by testing our comprehensive natural products collection
(Cuconati et al, in preparation) , which was donated to the Blumberg Institute by Merck & Co. in 2011.

Seeing is Believing:
Our computational chemists have created models of the intact hepatitis B virus that are 3-D depictions of the genome surrounded in its protein capsid home. We are using these images to help produce more potent capsid inhibitors.
Kulp et al, in preparation.

StephenW

2
乙型肝炎基金会2014年年度报告
未来三年将是“化妆是”时期为乙型肝炎基金会和研究机构中，
巴鲁克S. Blumberg的研究所。我们实行了一项雄心勃勃的时间表的结果，因为我们相信机会就是现在，而需要的是迫在眉睫。
我们的世界一流的研究机构，更名在2013年的巴鲁克S. Blumberg的学院荣誉
我们的共同创始人，诺贝尔奖获得者布隆伯格博士，有望显著加快研究步伐。我们聘请了一批一流的科学家加盟全职在布隆伯格
学院在2015年。
我们的新的科学家，但是，不是从零开始。事实上，他们将有，因为一个良好的开端
我们一直在准备，并为超过二十年建设朝着这个目标努力。而我们所有的
科学家们表示要确认突破的治疗乙肝在未来的三年。
我们希望和计划，我们发现从实验室到人类使用尽可能快地去了。
我们知道，这将需要与制药公司的经验药物研发专家，我们已经作出安排，以打造技术发展伙伴关系。这意味着，我们的科学家们可以专注于开创性的发现和我们的合作伙伴可以携带他们一路诊所。
我们希望在未来5到10年是简单 -
这完全治愈被发现，这将有利于全世界的每个人都患有慢性乙型肝炎。
我们准备做一个大胆的新推真正使乙肝病史。

新的方法来治疗乙肝

把STING在乙型肝炎：
使用博士的实验室开发了一种创新的试验。郭畅，治疗乙肝的新方法被发现。我们的小分子“干扰素基因刺激”（STING）是在该领域，并显示最激动人心的线索1
在组织培养的所有可检测的病毒基因产物可以被消除。这一发现在小动物研究证实了。该STING方法已经转移到了我们的研究策略前，是比较创新的免疫治疗方法之一。
Guoet人，抗菌剂与化疗，2014年。

乙肝表面抗原抑制剂：
我们已经开发出了一些针对乙型肝炎病毒表面上的唯一的药物
抗原（HBsAg）。的HBsAg是病毒复制所必需的，并且还帮助避免病毒检测由患者的免疫系统。我们已经制作了几个
药物减少的HBsAg由受感染的细胞分泌的量，在组织培养中。动物结果正在进行，尚未定论的数据。但是，这是一个
非常有前途的治疗方法。
Cuconati等人，在准备。

衣壳抑制剂：
我们已经确定了病毒衣壳组装过程的新型抑制剂。衣壳是蛋白护罩包围的病毒DNA和是一个重要的蛋白质。它也可以在调节从病毒基因表达中发挥作用的
共价闭合环状（CCC）DNA以及免疫逃避。我们的新的衣壳抑制剂已经显示出是病毒产量的有效抑制剂在体外（组织培养），甚至可以具有免疫改变功能。一类我们的化合物已被证实为有效的动物研究中，太。
平原等人，J病毒学，2013。

cccDNA的抑制剂：
我们已经确定了抑制乙肝cccDNA的（刘等人，2013年，PLOS病原体）的化合物，并且在其发展的极大兴趣。一些线索都是由测试我们全面的天然产品集合发现
（Cuconati等，筹建中），这是捐赠给了布隆伯格研究所由默克公司于2011年。

眼见为实：
我们的计算化学家已经创建了完整的乙型肝炎病毒是包围在它的蛋白质衣壳家基因组的3-D描绘的模型。我们正在利用这些图像，以帮助生产更有效的衣壳抑制剂。
库尔普等人，在准备。

newchinabok

回复 StephenW 的帖子

找不找到arwr箭头2014年报呀，

战天斗hbv

And all of our scientists have pledged to identify breakthrough therapies for hepatitis B in the next three years.
Our hope for the next 5 to 10 years is simple—
that a complete cure is found, which will benefit everyone living with chronic hepatitis B worldwide.
We are ready to make a bold new push to truly make hepatitis B history.


标红的字为
在接下来三年内
5到10年是非常简单的
一个完全治愈方案

战天斗hbv

大快人心

newchinabok

这是下一波药，还早。先看眼前这一波，这一波药不多了

newchinabok

arc520上市应该是没问题，期待arc520和核苷组合，期待，birinapant

StephenW

回复 newchinabok 的帖子

乙型肝炎基金会其布隆伯格研究所(Blumberg)自身进行HBV研究, 并与像箭头，Novir等公司竞争.现在，Tekmira/ Oncore合约了很多研究与HBF.布隆伯格研究所有许多中国人美国科学家（记得eantigent生物科学，被Oncore收购).

重韧

这个研究所是不是有跟Oncore有合作，好像以前哪里看到过一样。不过未来三年，2018有新药的突破，这个跟现有的速度差不多。。

StephenW

回复 重韧 的帖子

是有跟Oncore有合作.